YM

Yamini Matha

Active Director Designated Partner DIN 11553027
DIN 11553027 First appointment Feb 2026 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Yamini Matha

Data last updated:

Yamini Matha is a Designated Partner at Next Zen Pharmaceuticals Llp (since 2026). The company operates in Pharma.

DIN 11553027
Primary Designation Designated Partner
Industry Pharma
First Appointment 18 Feb 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner18 Feb 20262026Active

Board colleagues of Yamini Matha

NameDINCompanyDesignation
Nancy Kathrine Mede11553026Next Zen Pharmaceuticals LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Next Zen Pharmaceuticals Llp
Premium access

Shareholding and investment profile for Yamini Matha

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Yamini Matha

Yamini Matha currently holds 1 directorship: Next Zen Pharmaceuticals Llp (Designated Partner, since 18 Feb 2026).

Yamini Matha was first appointed on 18 Feb 2026 as Designated Partner at Next Zen Pharmaceuticals Llp.

The current boards of Yamini Matha's companies include Nancy Kathrine Mede (Next Zen Pharmaceuticals Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available